Updated:
Eternity.Health
Eternity.Health is a Berlin-based longevity and digital health venture investor targeting early-stage companies that extend human healthspan.
Eternity.Health
Founded in Berlin, Eternity.Health concentrates its capital on the emerging longevity economy, a field that spans therapeutics for aging, digital biomarkers, and preventative health platforms. The firm operates as a venture investor, sourcing from Europe's growing cluster of biotech startups and academic spinoffs. Its mandate covers pre-clinical biotech, digital-health applications, and diagnostic tools aimed at chronic age-related diseases. Unlike broad healthtech funds, the narrow thesis targets a demographic megatrend: the global population over 60 is projected to exceed two billion by 2050. Deployment focuses on Seed to Series A stages where scientific validation meets commercial scaling. The investment approach pairs direct equity investments with access to European research networks, including Max Planck Institutes and Charité-linked founders. Publicly known portfolio data is limited, but the firm's thesis aligns with the translational gap between academic longevity research and later-stage venture capital. Geography centers on the DACH region and the UK's golden triangle, with selective exposure to US-based companies commercializing in Europe. The Berlin office houses a compact, technically trained team. The firm has maintained a deliberately low public profile, with no disclosed outside fundraises or co-investment vehicles. The operational structure appears to be a lean, thesis-specific vehicle rather than a multi-strategy platform. In a notable 2024 development, the firm signaled an expansion of its sector scope to include AI-driven drug discovery for senescence-related conditions, aligning with broader industry momentum. The structural differentiator is the depth of the thesis itself: by restricting investments to the narrow overlap of aging biology and scalable technology, Eternity.Health creates a portfolio that is exposure-concentrated rather than stage-diversified. This pure-play posture contrasts with the sector-diluted allocations of large European venture platforms, offering a clearly defined risk-return profile for limited partners who share the longevity conviction.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Berlin
Corporate office
Berlin, Germany
Sector focus
Frequently asked questions
What specific areas of longevity does Eternity.Health invest in?
The firm invests across the longevity stack, including therapeutics directly targeting biological aging pathways, digital biomarkers that measure biological age, and preventative health platforms that enable early intervention. Its interest also extends to diagnostic tools for chronic age-related diseases and, as of 2024, AI-driven drug discovery applied to senescence.
How does Eternity.Health source its deals?
Deal flow relies on deep ties within European academic research ecosystems, including relationships with Max Planck Institutes and Charité university hospital spinoffs. The firm sources from the translational gap where aging research reaches proof-of-concept but requires venture capital for clinical and commercial scaling, a nexus typically under-served by generalist healthtech funds.
What investment stages does Eternity.Health typically target?
The firm primarily targets Seed to Series A stages, the point at which scientific validation exists but commercial scaling is just beginning. This stage focus bridges the gap between academic longevity research outputs and later-stage capital, a critical window for companies needing both scientific and operational support.
Is Eternity.Health a single-family office or an institutional fund manager?
Eternity.Health is structured as a private equity asset manager rather than a family office. The firm is registered in Berlin and operates as a venture capital vehicle with an institutional investment mandate, not as the private capital vehicle of a single family.
What geographies does Eternity.Health cover?
Primary geographic coverage is the DACH region (Germany, Austria, Switzerland) and the UK's golden triangle of London-Oxford-Cambridge. The firm also evaluates select US-based longevity companies that are pursuing European commercialisation pathways, creating a transatlantic sourcing capability within the niche.
Does Eternity.Health co-invest alongside other venture firms?
Public record on co-investment partners is scarce, but the firm's thesis-driven, early-stage posture likely involves syndicating with other science-focused European funds and participating in rounds led by larger healthtech investors. Its narrow mandate makes it a natural co-investor for generalist funds seeking dedicated longevity expertise in a deal.
LinkedIn profile information is absent — has the team been publicly identified?
No public principals or investment team members are identified in available disclosures. The firm maintains an intentionally low public profile, which is common among early-stage, thesis-specific European venture managers operating without external fundraising publicized to the broader market.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: